ARTICLE | Emerging Company Profile
Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compounds
By Danielle Golovin, Senior Biopharma Analyst
May 8, 2024 6:01 PM UTC
Avicenna is applying its machine learning platform to medicinal chemistry to accelerate small molecule development, essentially skipping the lengthy hit-to-lead phase and instead going directly to optimizing a clinical candidate.
Companies can spend several years and millions of dollars finding a hit compound that works well in vitro, only to run into issues with off-target toxicity, poor PK or suboptimal tissue distribution in vivo…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652350/avicenna-using-machine-learning-to-skip-the-hit-to-lead-phase